News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

GARNET updates confirm long-term dostarlimab benefit in dMMR/MSI-H endometrial cancer
09 Jul 2026
byAudrey Abella
Updates from the GARNET trial underpin dostarlimab monotherapy as a meaningful treatment option for women with mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) advanced/recurrent endometrial cancer (A/R EC) who progressed after prior platinum therapy.







![[VIDEO]: Achieving Enhanced Recovery After Surgery objectives with ropivacaine](https://cdn.mspprd.mims.com/images/articles/video-achieving-enhanced-recovery-after-surgery-objectives-with-ropivacaine-85252040-698a-428d-a6c0-43acd5b18e5c-square.jpg)
